1227588-49-9

Basic information

• Product Name: 3-broMo-5-chloropyridine-2-carbaldehyde
• Synonyms: 3-broMo-5-chloropyridine-2-carbaldehyde;3-BROMO-5-CHLOROPICOLINALDEHYDE
• CAS NO: 1227588-49-9
• Molecular Formula: C6H3BrClNO
• Molecular Weight: 220.45112
• Mol File: 1227588-49-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-broMo-5-chloropyridine-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-broMo-5-chloropyridine-2-carbaldehyde(1227588-49-9)
• EPA Substance Registry System: 3-broMo-5-chloropyridine-2-carbaldehyde(1227588-49-9)

Safety Data

• Hazardous Substances Data: 1227588-49-9(Hazardous Substances Data)

Upstream product

• 90902-83-3 3-amino-2-bromo-5-chloropyridine 
• 137628-17-2 2,3-dibromo-5-chloro-pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 131036-39-0 3-bromo-5-chloro-2-methylpyridine 

Relevant articles and documents

6,7-HETEROCYCLIC FUSED 5H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES AND THEIR USE AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TD02) MODULATORS

This invention relates to novel compounds of formula (I) wherein 'A' is a 5 or 6 membered heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1RB1)n-; Y is selected from: a bond, -(CRDRE)m-, -O-, -NRF, -S-, -C(O)-, -C(NRF) -, -C(ORF)Rc-, -C(NRFRG)RC-, -C(O)NRF, -NRFC(O)-, -NRFC(O)NRG-, - NRFSO2NRG-, -SO2-, -SO2NRF-, -NRFSO2-, -OC(O)- and -C(O)O-; Z is a bond or -(CRA2RB2)k-; wherein m, n and k are each independently selected from 1, 2, 3 and 4; R1 is H or a 3 to 16 membered fully saturated, partially unsaturated or aromatic mono-, di- or tri-cyclic moiety, which optionally may include 1, 2 or 3 heteroatoms selected from O, N and S, and which is unsubstituted or substituted with 1 to 5 substituents as defined in claim 1; R2 is selected from: H, halo, C1-4alkyl, C1-4 haloalkyl, -ORA4 and C1-4alkyl substituted with -ORA4; and R3 and R4 are each independently selected from: H, halo, C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, -ORA4, -NRA5RB4, -CN, -SRAS and C1-4alkyl substituted with -ORA5; and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3- dioxygenase (TD02) modulators (e.g. IDOl, and ID02 and/or TD02 inhibitors).

COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS

The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.